Edesa Biotech increases equity plan shares by 750,000 and removes option grant limits

Edesa Biotech's board approved Amendment No. 5 to its 2019 Equity Incentive Compensation Plan, effective March 18, 2026, increasing reserved shares by 750,000 and eliminating annual option grant limits per participant. The amendments require shareholder approval at the 2026 Annual General Meeting and reflect the company's intent to expand equity compensation flexibility.